Oramed Pharmaceuticals raises $2m.

Jerusalem-based Oramed Pharmaceuticals announced on Monday that it has successfully completed a $2 million capital campaign The placement was at $0.50 per share with a warrant priced at $0.75.

By MATTHEW KRIEGER
August 7, 2007 07:59

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Jerusalem-based Oramed Pharmaceuticals announced on Monday that it has successfully completed a $2 million capital campaign The placement was at $0.50 per share with a warrant priced at $0.75. Oramed, a leading developer of the oral insulin gel capsule is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The company is also pursuing the development of oral delivery solutions for other drugs and vaccines. The $2m. financing, raised by a number of leading private investors, will allow the company to fully focus on its research and development efforts and complete phase 1 product trials, which will ensure that there are both no negative side effects in healthy humans as well as help formulate the proper dosage for diabetic patients in the future.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS